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Abstract
Background: Neurocysticercosis, infection of the brain with larvae of Taenia solium (pork tapeworm), is one of several forms
of human cysticercosis caused by this organism. We investigated the role of albendazole and praziquantel in the treatment
of patients with parenchymal neurocysticercosis by performing a meta-analysis of comparative trials of their effectiveness
and safety.
Methods and Principal Findings: We performed a search in the PubMed database, Cochrane Database of Controlled Trials,
and in references of relevant articles. Six studies were included in the meta-analysis. Albendazole was associated with better
control of seizures than praziquantel in the pooled data analysis, when the generic inverse variance method was used to
combine the incidence of seizure control in the included trials (patients without seizures/[patients6years at risk]) (156
patients in 4 studies, point effect estimate [incidence rate ratio]=4.94, 95% confidence interval 2.45–9.98). In addition,
albendazole was associated with better effectiveness than praziquantel in the total disappearance of cysts (335 patients in 6
studies, random effects model, OR=2.30, 95% CI 1.06–5.00). There was no difference between albendazole and praziquantel
in reduction of cysts, proportion of patients with adverse events, and development of intracranial hypertension due to the
administered therapy.
Conclusions: A critical review of the available data from comparative trials suggests that albendazole is more effective than
praziquantel regarding clinically important outcomes in patients with neurocysticercosis. Nevertheless, given the relative
scarcity of trials, more comparative interventional studies—especially randomized controlled trials—are required to draw a
safe conclusion about the best regimen for the treatment of patients with parenchymal neurocysticercosis.
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Introduction
Neurocysticercosis is a parasitic disease caused by the larval
form of Taenia solium, known as pork tapeworm, when the larvae
lodge in the central nervous system (CNS). It happens when
human ingests the eggs, acting as the intermediate host in the life
cycle of T. solium. The eggs hatch in the intestine and the embrya
penetrate the intestinal wall and are distributed via the blood,
anchoring in the CNS as a larval form of the parasite [1]. With T.
solium parasitosis, both self-reinfection and infection of household
members are common.
Neurocysticercosis is mosst commonly found among members
of agricultural societies with poor sanitary conditions and
economies based on breeding livestock, especially pigs, with low
hygiene standards [2]. However, it has also started to emerge in
developed countries, as a result of immigration from endemic to
nonendemic areas [3]. Its natural pool lies mainly in Latin
America, sub-Saharan Africa, and Southeast Asia, and is an
important cause of morbidity among local populations [2].
Neurocysticercosis is divided into four categories depending on
the anatomical locus in which the larvae lodge—cerebral or
parenchymal, subarachnoid or cisternal, intraventricular, and
spinal [1]. The most common clinical sign of neurocysticercosis is
epilepsy of any type, which is usually late-onset; this sign is
typically found in parenchymal neurocysticercosis. Other common
signs are focal neurological deficits, cerebellar or brainstem signs,
signs of increased intracranial pressure, meningoencephalitic signs,
dementia, or even death [4].
The standard therapeutic intervention was surgery until the
development of cysticidal agents, the most common being
praziquantel and albendazole [5]. Although there have been
many clinical trials testing these drugs, controversy remains about
their therapeutic value [5]. The reasons for this dispute include
the severity of adverse effects, the actual reduction of cysts, and
the subsequent control of seizures. This disagreement seems to
have been resolved after the recent publication of a meta-analysis
that shows the superiority of these agents compared to placebo
[6].
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in the treatment of neurocysticercosis. Some studies have been
published on this issue, although they mostly examine small
numbers of patients. Specifically, we investigated the role of
albendazole versus praziquantel in the treatment of patients with
parenchymal neurocysticercosis by performing a meta-analysis of
comparative trials [7] of their effectiveness and safety.
Methods
Data sources
The studies for our meta-analysis were obtained from the
PubMed database, Cochrane Database of Controlled Trials, and
from references of relevant articles. Search terms included
‘‘albendazole’’, ‘‘praziquantel’’, ‘‘neurocysticercosis’’, and ‘‘Taenia
solium’’. Although the search was performed without limitation on
the language of publications, the evaluable studies were published
in English, French, German, and Italian. There was no limitation
on the year of publication.
Study selection
Two independent reviewers (DKM and GP) performed the search
and selected the studies that were relevant to the scope of our meta-
analysis. Any discrepancy or disagreement between the reviewers was
resolved by consensus in meetings involving all authors. A study was
considered eligible if (1) it was a prospective trial, (2) it compared
albendazole with praziquantel for the treatment of patients with
neurocysticercosis, (3) it examined the partial or total disappearance
of cysts and/or control of seizures, and (4) if it included patients
infected with parasites in their cystic stage without perilesional
inflammation. Studies using concomitant drugs such as corticoste-
roids, analgesics, and anticonvulsive drugs were not excluded.
Data extraction
The following data were extracted from each study: year of
publication, study design, population of the study, therapeutic
regimens used, concomitant drugs, number of patients, follow-up
period, patients having control of seizures, proportion of cyst
reduction, disappearance of cysts, total toxicity, and patients
presenting intracranial hypertension as a side effect. A quality
review of each randomized controlled trial (RCT) included in our
analysis was performed by using the Jadad score, which examines
whether there is randomization, blinding, and information on
withdrawals in the study, and evaluates the appropriateness of
randomization and blinding, if present. One point was awarded
for the presence of each of the first 3 criteria, whereas the last 2
criteria could take the values of 21 (inappropriate), 0 (no data),
and +1 (appropriate) [8,9]. Thus, the maximum score for a study
was 5, and a score more than 2 points denoted an adequate RCT
according to the methodology. The reviewers calculated the score
of each RCT independently. Any disagreement was resolved after
consensus among all authors.
Outcomes
The primary outcome was the proportion of patients with
controlled seizures. Secondary outcomes were the reduction of
cysts in all of the examined patients, the proportion of patients
with total disappearance of cysts, the proportion of patients with
adverse events related with the administered antihelminthic drugs,
and the proportion of patients with intracranial hypertension as a
side effect caused by the administered drugs.
Definitions
A patient was considered as having total control of seizures
when there had been no seizures during the follow-up period. A
patient was considered as having total disappearance of cysts when
this outcome had been achieved after only one course of
administered chemotherapy and without any surgical intervention
at the follow-up CT scan, performed in a time frame of 3 to
6 months after the end of therapy. The reduction of cysts was
defined as the proportion of the number of cysts that had resolved
by the follow-up evaluation (numerator), which varied from 3 to
6 months post-therapy, divided by the number of cysts at baseline
(denominator). Adverse events included any type of adverse event
reported in the included studies.
Statistical analyses
Statistical analyses were performed using the ‘‘Review Manager
4.2’’ software and the SPSS 15.0 statistical software. The
heterogeneity between studies was assessed by using the I
2 test
and x
2 test; for the x
2 test, p,0.10 was considered statistically
significant in the analysis of heterogeneity [10]. Small-study bias
was assessed by the funnel plot method [11]. Pooled odds ratios
(ORs) and 95% confidence intervals (CIs) for all primary and
secondary outcomes were calculated by using both the Mantel-
Haenszel [12] fixed effect model and the DerSimonian-Laird
random effects model [13]. For all analyses, results from the fixed
effect model are presented only when there was no heterogeneity
between studies; otherwise, results from the random effects model
are presented. For the analyses of proportions of the reduction of
cysts, we used a linear regression model in which the percentage of
reduction of cysts for each treatment arm in the included studies
was the dependent variable, and the administered drug was the
independent variable. With this model, a beta (b) coefficient of the
independent variable was calculated as well as the 95% confidence
interval (CI) of the coefficient. For the analyses of seizure control
for which the follow up period varied, we combined the logarithms
of the rate ratios across the included trials (patients with outcome/
[patients6years at risk]) using the generic inverse variance
method.
Author Summary
Neurocysticercosis is a parasitic disease caused by the pork
tapeworm, Taenia solium, when the larval form of the
parasite lodges in the central nervous system. This disease
is most commonly found among members of agricultural
societies with poor sanitary conditions and economies
based on breeding livestock (especially pigs) with low
hygiene standards. It is a disease with long history in
humans, and the usual therapeutic intervention was
surgery until the development of antiparasitic cysticidal
agents, the most common being praziquantel and
albendazole. T. solium infection can take many different
forms in humans, but we concentrated on parenchymal
neurocysticercosis with viable cysts. A consensus state-
ment by a panel of experts on the subject supports the use
of antiparasitic treatment, but does not indicate either
albendazole or praziquantel as the drug of choice for this
type of neurocysticercosis, because data from single
relevant clinical trials are not conclusive. We conducted a
meta-analysis to further evaluate the comparative effec-
tiveness and safety of albendazole and praziquantel for
this particular type of neurocysticercosis. The outcomes of
our meta-analysis suggest that albendazole is more
effective than praziquantel in controlling seizures in
affected patients and in leading to the total disappearance
of cysts and subsequently cure of patients with neurocys-
ticercosis.
Treatment of Neurocysticercosis
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Selection of the trials
Figure 1 is a flow diagram describing the process of study
selection. We identified 103 potentially evaluable papers, 91 of
which were excluded because they were reviews, case reports,
letters or editorials, laboratory studies, small series of patients,
retrospective studies, and meta-analyses that examined a different
aspect of neurocysticercosis than the comparison between
praziquantel and albendazole. Of the remaining 12 potentially
evaluable papers, 2 studies were excluded because they included
patients with neurocysticercosis that was not parenchymal, 1
because the majority of the enrolled patients had mixed living and
calcified cysts, 1 because the enrolled patients were all put in the
same group without providing separate data for each antiparasitic
agent, and 2 because they were subsets of other larger trials. Thus,
6 trials were included in our meta-analysis [14–19].
Quality assessment
The assessment of the evaluable studies according to the Jadad
score was performed only for the 2 out of 6 studies [15,19]. The
rest of the studies were prospective [14,16–18] but not RCTs.
Thus, quality assessment of these trials using Jadad could not be
done.
Administration of study drugs
The studies differed in the administered dosing and duration of
therapy for albendazole and praziquantel (Table 1). Most of the
researchers administered 15 mg/kg/d of body weight of albenda-
zole, but the duration of therapy varied from 8 days to a month
[14–16,18,19]. In only one study albendazole was administered at
a dosage of 20 mg/kg/d for 21 days [17]. We pooled these data,
as the administration of albendazole for 7 days is as effective as for
longer periods of therapy [20]. There was notable variation in the
duration of praziquantel therapy, extending from a single day to
3 weeks. In all of the studies the dosage of praziquantel was
50 mg/kg/d, except one study in which praziquantel was
administered at a dosage of 100 mg/kg in 3 divided doses at 2-
hour intervals for a single day [14]. We pooled these data, as the
administration of praziquantel for a single day is as effective as for
longer periods of therapy [21–23].
Control of seizures
Data on the complete control of seizures in patients with
neurocysticercosis treated with albendazole or praziquantel were
reported in 4 out of 6 studies (Table 2) [14–17]. One study
reported a statistically significant effects in favor of albendazole, as
reported in the crude data provided in the study [17]. To
overcome the variation in the follow-up periods, we used the
generic inverse variance method to combine the incidence of
seizure control (patients without seizures/[patients6years at risk])
of the included trials (Table 2). Albendazole was associated with
better control of seizures in comparison with praziquantel in the
pooled data analysis (156 patients, random effects model
[I
2=51.2%], point effect estimate [incidence rate ratio]=4.94
[seizure-free persons/person-years], 95% CI 2.45–9.98, Figure 2).
Reduction of cysts
Data on the reduction of the total number of cysts from baseline
to follow-up are reported in 5 out of 6 studies (Table 2) [14–17,19].
A linear regression model of the proportion of reduction of cysts
and the administration of albendazole or praziquantel yielded a
beta coefficient (b)=0.22 (standard error [SE]=0.113) with 95%
CI 20.05 to 0.48. The analysis included a total of 301 patients
with 2565 cysts. Hence, there was no statistically significant
difference in the proportion of the reduction of cysts between
albendazole and praziquantel for the treatment of neurocysticer-
cosis. In addition, in a sensitivity analysis excluding the data
reported in the RCT by Sotelo et al [19] which comprised almost
one half of the total number of cysts, there was no statistically
significant difference in the proportion of the reduction of cysts
between albendazole and praziquantel for the treatment of
neurocysticercosis (b=0.15 [SE=0.18], 95% CI 20.30 to 0.59).
The analysis included a total of 187 patients with 1342 cysts.
Total disappearance of cysts
Data on the total disappearance of cysts are reported in all 6
studies (Table 2) [14–19]. Albendazole was associated with greater
Figure 1. Flow diagram of reviewed articles.
doi:10.1371/journal.pntd.0000194.g001
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patients, random effects model (x
2-test p=0.07, I
2=50.3%),
OR=2.30, 95% CI 1.06–5.00, Figure 3). Since in the study by
Cruz et al [18] it is not clear whether the patients with cystic
lesions also had lesions involving other stages of the infection, we
performed a sensitivity analysis without the aforementioned study,
in which albendazole was more effective than praziquantel in
inducing the total disappearance of cysts (301 patients, random
effects model (x
2-test p=0.05, I
2=58.1%), OR=2.62, 95% CI
1.09–6.32). We also performed a sensitivity analysis excluding data
reported in the RCT by Sotelo et al [19], which included almost
one-third of the total number of patients in this meta-analysis and
showed statistical significance. There was no difference between
the two regimens in inducing the total disappearance of cysts (221
patients, random effects model (x
2-test p=0.08, I
2=52.5%),
OR=2.20, 95% CI 0.79–6.13).
Mortality
Data about mortality are reported in all 6 studies (Table 2) [14–
19]. One death was reported in by Takayanagui et al [17] due to
increased intracranial pressure. These data were not adequate to
allow a meaningful analysis.
Total adverse events
Data about patients with adverse events are reported in 5 out of
6 studies (Table 2) [14,15,17–19]. Albendazole and praziquantel
did not differ in the proportion of patients with adverse events (388
patients, random effects model [x
2-test p=0.06, I
2=59.9%],
OR=0.67, 95% CI 0.26–1.69).
Intracranial hypertension
Data on intracranial hypertension developing as a consequence
of the regimens administered are reported in 4 studies (Table 2)
[14,16–18]. There was no difference in the development of
intracranial hypertension due to the administered therapy between
albendazole and praziquantel (179 patients, fixed effect model [x
2-
test p value=0.58, I
2=0%], OR=0.31, 95% CI 0.05–2.09).
Discussion
Neurocysticercosis is an endemic disease in many developing
countries, and it may expand to the developed world, mainly as a
result of immigration. Estimations report around 50 million new
cases worldwide [24]. To our knowledge, until now the guidelines
for the treatment of cysticercosis are the result of a consensus by a
panel of experts in the subject [25]. Specifically, for viable
parenchymal cysts the recommendations are based on evidence
obtained from multiple case series with or without intervention,
including dramatic results in uncontrolled experiments (level II-3
recommendation, which is considered a weak category of
evidence), and on opinions of respected authorities, based on
clinical experience, descriptive studies, and case reports or reports
of expert committees (level III recommendation). Although these
recommendations support the use of antiparasitic treatment, they
Table 1. Main characteristics of the selected trials.
Author-
Year
Type of infection-
Setting-Country
Jadad
score
* 1
st regimen 2
nd regimen
Concomitant
therapy
No. of
patients
(total-ALB-
PZQ) Follow-up
Del Brutto
et al 1999
[14]
Prospective study -
Parenchymal NCC with viable
cysts and without CT evidence
of surrounding inflammation -
Ecuador
— Albendazole
15 mg/kg/d in two
divided doses for
1 week
Praziquantel
100 mg/kg in three
divided doses at 2
hour intervals for 1 day
AED,
corticosteroids,
analgesics,
antiemetics
20-10-10 CT scans after
3 months, 6–
12 months total
follow-up
Carpio et al
1995 [15]
Open RCT – Active
parenchymal NCC without
enhancement with contrast
media in CT and with or
without calcifications - Ecuador
3 Albendazole
15 mg/kg/d for
8 days
Praziquantel
50 mg/kg/d for
15 days
AED,
corticosteroids
111-57-54 CT scans between 3–
6 months and 9–
12 months, 2 years
total follow-up at
2 month intervals
Medina et al
1993 [16]
Prospective study –
Parenchymal NCC without
CT evidence of surrounding
inflammation - Mexico
— Albendazole
15 mg/kg/d for
8 days
Praziquantel
50 mg/kg/d for
8 days
AED 16-11-5 CT scans and/or MRI
after 3 months, 10–
18 months total
follow-up at 3 month
intervals
Takayanagui
et al 1992
[17]
Prospective study -
Parenchymal NCC with non-
enhancing cystic lesions - Brazil
— Albendazole
20 mg/kg/d for
21 days
Praziquantel
50 mg/kg/d for
21 days
AED,
corticosteroids
43-21-22 CT scans after
6 months, CSF analyses
after 1 month
Cruz et al
1991 [18]
Prospective study –NCC of
any developmental phase
of the parasite - Ecuador
— Albendazole
15 mg/kg/d for
30 days
Praziquantel
50 mg/kg/d for
15 days
AED,
corticosteroids,
analgesic,
symptomatic
medication
100-50-50 CT scans after
3 months, 3 months
follow-up for
recurrence
Sotelo et al
1990 [19]
RCT - Parenchymal NCC
without CT evidence of
surrounding inflammation -
Mexico
3 Albendazole
15 mg/kg/d for 1
month (group III)
and 15 mg/kg/d for
8 days (group IV)
Praziquantel
50 mg/kg/d for
15 days (group I)
and 50 mg/kg/d for
8 days (group II)
AED,
corticosteroids,
analgesics,
antiemetics
114-49-65 CT scans after
3 months
*The two reviewers were concordant in the assessment of the scores of the included studies.
AED, antiepileptic drugs; ALB, Albendazole; CT, computed tomography; MRI, magnetic resonance imaging.NCC, neurocysticercosis; PZQ, Praziquantel; RCT, randomized
controlled trial.
doi:10.1371/journal.pntd.0000194.t001
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choice for this type of neurocysticercosis.
In a recent meta-analysis performed by Del Brutto et al. [6] it
was suggested that, compared to placebo, cysticidal drug therapy
results in better resolution of colloidal and vesicular cysticerci,
lower risk for recurrence of seizures in patients with colloidal
cysticerci, and a reduction in the rate of generalized seizures in
patients with vesicular cysticerci. However, there has not yet been
a meta-analysis comparing the effectiveness and safety of
albendazole and praziquantel in patients with neurocysticercosis.
The outcomes in our meta-analysis suggest that albendazole is
more effective than praziquantel in controlling seizures in the
affected patients and in leading to the total disappearance of cysts
and, subsequently, the cure of patients with neurocysticercosis.
However, in the sensitivity analysis of the total disappearance of
cysts, excluding the study by Sotelo et al [19], no significant
difference was found between the drugs, although the odds ratio
was rather similar to the analysis that included the study by Sotelo
et al. [19]. This loss of statistical significance can be explained by
the loss of power in the sensitivity analysis due to exclusion of the
aforementioned study. Regarding other outcomes, there have been
no statistically significant differences between albendazole and
praziquantel in reduction of total number of cysts, mortality, total
adverse events, and development of intracranial hypertension due
to the administered therapeutic agents. Control of seizures and
total disappearance of cysts were chosen as outcomes in our meta-
analysis, because they are easily defined and quantitatively
measured. In addition, new-onset seizures are among the most
common symptoms that lead patients to seek medical care, and
their resolution is one of the major goals of therapy.
In the analyses of outcomes we did not perform sensitivity
analyses that excluded the study by Medina et al [16], in which
patients did not receive corticosteroids. Since it is the only study
with this characteristic, one may suggest that it could cause bias. It
might be speculated that the absence of corticosteroids could
interfere with the kinetics of the administered antihelminthics, and
cause an increase in the rate of the adverse events. However, all
the outcomes included in this study did not differ from the results
of the other trials; adverse events are not reported in this study.
The reduced effectiveness of praziquantel could be explained by
the interaction between praziquantel and corticosteroids, which
results in decreased serum concentration of praziquantel [26].
Also, praziquantel interacts with anti-epileptic drugs [27,28], thus
altering its bioavailability. In contrast, corticosteroids interact with
albendazole by decreasing the rate of elimination of albendazole
sulfoxide, which is the active metabolite of albendazole, thus
increasing serum concentrations of albendazole sulfoxide [29,30].
Often, the first few days after the administration of antiparasitic
agents to patients with neurocysticercosis there is a recrudescence
of neurological symptoms, most importantly decompensation of
intracranial pressure and the onset of seizures or worsening of pre-
existing ones, owing to peri-lesional inflammation due to
degeneration of the parasite; this condition can be life-threatening.
The severity of inflammation is proportional to the parasitic
burden, resulting in more severe manifestations in individuals with
greater cyst loads [31]. A common approach to ameliorating this
problem is the concomitant administration of corticosteroids to
reduce edema, the inflammatory response, and intracranial
hypertension [32]. Special attention should be paid to patients
with high cyst loads, to whom the administered antiparasitic
treatment causes an abrupt degeneration of cysts that may lead to
severe inflammation and seizures [5]. In such cases corticosteroids
should be administered before the antiparasitic agents. The single
death reported in the study by Takayanagui et al [17] (the only
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was the result of increased intracranial pressure, which, however,
pre-existed at the beginning of the trial. In 5 out of 6 studies
included in our meta-analysis, corticosteroids were administered to
patients [14,15,17–19]. Only in the study by Medina et al [16]
were corticosteroids not administered; adverse events were not
reported in this study.
It is believed by several experts that many cysts degenerate
spontaneously over time, which may lead to the conclusion that
the results of the evaluable studies may be biased [33]. Since it is
not clear up to what extent this opinion is true, we analyzed studies
that included patients with cystic lesions without perilesional
enhancements or other evidence of surrounding inflammation, as
evidence of a possible degenerative process, to rule out such a
possibility. Antihelminthic drugs are effective against viable cysts,
but not on remnants, granulomas, and calcifications of dead cysts.
Thus, both outcomes we chose to study—the total disappearance
of cysts and reduction of cysts—are useful indicators of the
effectiveness of the administered therapy, because they estimate
the effectiveness of the administered agents for lesions on which
the agents are active.
There are some limitations in our meta-analysis that should be
considered. First, one may claim that the number of the studies
and the number of patients are too small to allow a definitive
conclusion regarding the results of the compared therapies. This
small sample size is important because it leads to large confidence
intervals. In addition, publication bias cannot be appropriately
assessed in a small set of studies. Also, among the studies selected
there are only 2 RCTs [15,19] in a total of 6 comparative trials,
which prevents us from applying the usually applied methodology
in obtaining an overall quality assessment of the included studies
[8].
Second, there are discrepancies in the administered dosage and
duration of therapy with the 2 antiparasitic agents used. Although
there have been several studies aiming to establish an optimal
dosage and duration of therapy, these important therapeutic
parameters have not been standardized yet. We pooled all of the
available data, since the dosage and the duration of therapy used
in the trials included in this meta-analysis are generally accepted
alternatives by the medical community.
Furthermore, there were differences in the length of follow-up
for the control of seizures between the studies that varied from 6 to
24 months. This fact may give rise to methodological issues
regarding the validity of combining these studies without
considering the duration of follow-up. Thus, we performed an
analysis using the generic inverse variance method combining the
incidence of seizure control in the included trials (patients without
seizures/[patients6years at risk]), in which the effect of different
follow-up time is included. However, it should be noted that the
caveat in this methodology is the assumption that the risk for
Figure 3. Odds ratios of patients with total disappearance of cysts. Vertical line=‘‘no difference’’ point between the two regimens.
Square=odds ratio; the size of each square denotes the proportion of information given by each trial. Diamond=pooled odds ratio for all trials.
Horizontal lines=95% CI.
doi:10.1371/journal.pntd.0000194.g003
Figure 2. Odds ratios of control seizures in patients with neurocysticercosis treated with albendazole or praziquantel. Vertical
line=‘‘no difference’’ point between the two regimens. Square=odds ratio; the size of each square denotes the proportion of information given by
each trial. Diamond=pooled odds ratio for all trials. Horizontal lines=95% CI.
doi:10.1371/journal.pntd.0000194.g002
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tioned limitations, the contribution of the meta-analysis in the
literature sheds light in the subject given the scarcity of data.
In summary, neurocysticercosis is a disease with a long history
in humans and with many different stages. We concentrated on
parenchymal neurocysticercosis with viable cysts. The recommen-
dations suggest the administration of antiparasitic treatment with
concomitant use of steroids. This meta-analysis sought to provide
more accurate estimates of the comparative effectiveness and
safety of albendazole and praziquantel for this common parasitic
infection. Nevertheless, more studies, especially randomized
controlled trials, with homogeneous regimens and long follow-up
periods, are required to draw a clear conclusion about the best
regimen for the treatment of patients with parenchymal neuro-
cysticercosis.
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